Mangalam Drugs & Organics Limited Stock NSE India S.E.

Equities

MANGALAM

INE584F01014

Pharmaceuticals

Market Closed - NSE India S.E. 07:43:48 2024-04-26 am EDT 5-day change 1st Jan Change
100.7 INR -0.05% Intraday chart for Mangalam Drugs & Organics Limited +0.75% +2.60%
Sales 2022 4.48B 53.68M Sales 2023 3.7B 44.4M Capitalization 1.55B 18.58M
Net income 2022 197M 2.36M Net income 2023 12M 144K EV / Sales 2022 0.56 x
Net Debt 2022 859M 10.31M Net Debt 2023 859M 10.3M EV / Sales 2023 0.65 x
P/E ratio 2022
8.28 x
P/E ratio 2023
122 x
Employees 523
Yield 2022 *
-
Yield 2023
-
Free-Float 46.66%
More Fundamentals * Assessed data
Dynamic Chart
Mangalam Drugs & Organics Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Mangalam Drugs & Organics Limited Reports Earnings Results for the Half Year Ended September 30, 2023 CI
Mangalam Drugs & Organics Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Mangalam Drugs & Organics Limited Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Mangalam Drugs & Organics Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023 CI
Mangalam Drugs & Organics Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Mangalam Drugs & Organics Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022 CI
Mangalam Drugs & Organics Limited Reports Earnings Results for the First Quarter Ended June 30, 2022 CI
Mangalam Drugs & Organics Limited Reports Earnings Results for the Full Year Ended March 31, 2022 CI
Mangalam Drugs & Organics Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2022 CI
Mangalam Drugs & Organics Limited Announces Appointment of Shri Rakesh K. Milwani as an Additional Director (Non- Executive Non- Independent Director) CI
Mangalam Drugs & Organics Limited Announces Executive Changes CI
Mangalam Drugs & Organics Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021 CI
Mangalam Drugs & Organics Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021 CI
Mangalam Drugs & Organics Limited Announces Earnings Results for the First Quarter Ended June 30, 2021 CI
More news
1 day-0.05%
1 week+0.75%
Current month+9.34%
1 month+3.76%
3 months-0.49%
6 months-0.54%
Current year+2.60%
More quotes
1 week
99.60
Extreme 99.6
103.50
1 month
90.80
Extreme 90.8
107.40
Current year
90.80
Extreme 90.8
132.45
1 year
90.80
Extreme 90.8
132.45
3 years
90.80
Extreme 90.8
196.95
5 years
20.65
Extreme 20.65
196.95
10 years
4.20
Extreme 4.2
442.40
More quotes
Managers TitleAgeSince
Chief Executive Officer 70 96-04-15
Director of Finance/CFO - -
Compliance Officer 30 22-02-07
Members of the board TitleAgeSince
Chief Executive Officer 70 96-04-15
Director/Board Member 68 21-03-20
Director/Board Member 72 15-02-04
More insiders
Date Price Change Volume
24-04-26 100.7 -0.05% 20,220
24-04-25 100.8 -0.98% 24,396
24-04-24 101.8 +0.10% 23,278
24-04-23 101.6 +1.55% 39,805
24-04-22 100.1 +0.15% 32,546

Delayed Quote NSE India S.E., April 26, 2024 at 07:43 am EDT

More quotes
Mangalam Drugs and Organics Limited is an India-based manufacturer of active pharmaceutical ingredients (APIs) and intermediates. Under the Company's Fight Malaria Program, it supplies anti-malaria APIs worldwide. Its products include API, intermediates and specialty chemicals. Its API products include acyclovir, amodiaquine, artemether, artesunate, atazanavir sulfate, bisoprolol fumarate, chloroquine phosphate, furosemide and dolutegravir sodium. The Company's intermediates products include 4,6-Dichloro-5-Methoxy Pyrimidine; 4,7- dichloroquinoline; ortho phenoxy methane sulfonanilide; tenofovir alafenamide base, and tenofovir disoproxil base. Its specialty chemicals products include L (+)-menthol; 2,3-dihydrophthalazine-1,4-dione or phthalazine-1,4-dione, and 4-cynoethyl-2-methyl phenol. Its pipeline APIs (under development) include Ganaplacide (IH), Tafenoquine Succinate (IH) and Pretomanid (IH). Its pipeline APIs (developed at research and development) is Bictegravir Na (IH).
Calendar
More about the company